PatientsVille.com Logo

LOSS OF CONSCIOUSNESS and Lexapro

PatientsVille

LOSS OF CONSCIOUSNESS Symptoms and Causes

Reye syndrome is a rare illness that can affect the blood, liver, and brain of someone who has recently had a viral infection. It always follows another illness. Although it mostly affects children and teens, anyone can get it. It can develop quickly and without warning. It is most common during flu season. Symptoms include

  • Nausea and vomiting
  • Listlessness
  • Personality change - such as irritability, combativeness or confusion
  • Delirium
  • Convulsions
  • Loss of consciousness

If these symptoms occur soon after a viral illness, seek medical attention immediately. Reye syndrome can lead to a coma and brain death, so quick diagnosis and treatment are critical. Treatment focuses on preventing brain damage. There is no cure.

The cause of Reye syndrome is unknown. Studies have shown that taking aspirin increases the risk of getting it. Because of that, health care professionals now recommend other pain relievers for young patients.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for LOSS OF CONSCIOUSNESS

LOSS OF CONSCIOUSNESS treatment research studies

Lexapro clinical trials, surveys and public health registries


Find Drug Side Effect reports



Lexapro Side Effects

Anxiety (302)
Suicidal Ideation (293)
Depression (288)
Completed Suicide (284)
Dizziness (279)
Nausea (268)
Convulsion (244)
Fatigue (234)
Headache (205)
Condition Aggravated (200)
Feeling Abnormal (192)
Insomnia (189)
Loss Of Consciousness (169)
Fall (167)
Pain (161)
Tremor (159)
Diarrhoea (156)
Amnesia (142)
Agitation (139)
Aggression (136)
Hyperhidrosis (103)
Suicide Attempt (102)
Dyspnoea (100)
Asthenia (96)
Vomiting (96)
Confusional State (95)
Overdose (87)
Gun Shot Wound (85)
Abnormal Behaviour (81)
Chest Pain (78)
Somnolence (75)
Weight Increased (71)
Blood Pressure Increased (69)
Abdominal Pain (69)
Paraesthesia (64)
Hypertension (59)
Hyponatraemia (57)
Anger (56)
Irritability (56)
Pregnancy (55)
Grand Mal Convulsion (55)
Pulmonary Embolism (54)
Contusion (53)
Abdominal Pain Upper (52)
Palpitations (51)
Panic Attack (50)
Intentional Overdose (49)
Injury (49)
Malaise (48)
Mania (48)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<span style=' '>Lexapro is a permanent life long cure for any depression if you can survive the treatment.<span style='mso-spacerun: yes;'> I was prompted by a marriage counselor to go to my doctor and requ

About the third day, got sick. By the fifth day, side effects became stronger and the headache began within 5 minutes of taking the pill as did the eustation tube pressure. Complete list of side effects: Flu li

Beware of Lexapro, make sure you are carefully monitored and report the earliest feelings of suicidal ideation. My husband hanged himself after being on Lexapro for 11 days. He was lucky enough to survive but made two subsequent attempts before being

Bradycardia

Can lexapro be take with nitroglycerin?

Has anyone experienced amnesia or a black out episode from Lexapro? I experienced such an episode and would like to discuss with anyone who has had the same.

I am on Lexapro for a few weeks now. The other night i went out, had a few drinks (was not the driver) and I behaved VERY aggessively. Is this normal?????

I drove home for about 15 minutes and didn't remember driving. I told the dr and he didn't really know what to say.

I have been on lexapro for 10 months now and I am slowly trying to get off it. My main problem with the drug is sexual disfunction. trouble maintaining an erection and now total anorgasmia. (not able to orgasm at all). I thought this must have been b

I have been taking the minimum dosage of 5mg a day for 6 months. after about the 1st month I started gaining about 1lb a week until I started cutting back. The more I cut back the slower the wait gain. I'm down to 2.5mg per day and am no lo

I took Mucinex DM 1200mg once at 10:30 pm and again at 10:30 am. By noon I wasnt functional at all, I had severe loss of focus, my eyes were dilated, and I was really slow, on top of the usual side effects of being jittery and nauseous. Since

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

leg cramps, hair loss Would it be better to take Lisinopril?

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

I have experienced weight loss of a pound a month for the last 2 years, since taking 100 mcg per day. My dr. can find no cause for this loss. I also have taken Metformin for about the same amount of time.

I have seen a significant loss of hair after about three months. I went to my dermatologist and told her that I feel that it is from Solodyn and she sent me to have blood work done thinking I may be anemic or I have a thyroid problem.

Anon- I would say the weed would cause the MOST memory loss used over time also depending on how strong it is ie, (haze, kush....dro...regs from 60's with seeds) THE STONGER it is the faster the brain cells go! As far as the valium/dia

<strong>Found Celepram effective at the end of the 3rd week. Effectiveness lasted for around 14 days. Following period i experienced continualled short term memory loss, hallucinations of seeing stars, skin irritated rash, shortness of breath &

3 months child red all over, staring, screaming high pitched cry, tracking red lines from injection site, lowered consciousness, screaming for more than 2 hours worse upon lying down. Would not breastfeed for 8 hours. Dosed exhuasted and awoke with h

LOSS OF CONSCIOUSNESS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting EScitalopram PIndolol ONset of Action
Condition: Unipolar Depression
Interventions: Drug: escitalopram, pindolol;   Drug: escitalopram
Outcome Measures: MADRS score change between baseline and 2 weeks of treatment;   Response/remission (MADRS) at 6 weeks;   Adverse events;   Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups
2 Recruiting Lexapro®'s Efficacy After Dose Escalation in Remission Study
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram
Outcome Measures: Montgomery-Åsberg Depression Rating Scale (MADRS);   Hamilton Depression Rating Scale-17 items (HAM-D);   Hamilton Anxiety Rating Scale (HAM-A);   Clinical Global Impression-severity (CGI-S);   Clinical Global Impression-Improvement (CGI-I);   Beck's Depression Inventory(BDI);   WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF);   Clinically Useful Depression Outcome Scale (CUDOS);   Short From-36 Health survey (SF-36 Health survey)
3 Unknown  Circadian Effects of Escitalopram
Condition: Depression
Intervention: Drug: placebo/escitalopram
Outcome Measures: Resetting effect of Escitalopram on the circadian pacemaker;   Correlation between improvement in depression with Escitalopram and the degree of realignment between the timing of sleep and the timing of the biological clock.
4 Recruiting Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder
Conditions: Irritable Bowel Syndrome;   Panic Disorder
Intervention: Drug: Escitalopram
Outcome Measures: Gastrointestinal Symptom Rating Scale (GSRS).;   State Trait Anxiety Inventory (STAI).
5 Recruiting Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Conditions: Major Depressive Disorder;   Major Depressive Disorder, Recurrent, Unspecified;   Major Depressive Disorder, Single Episode, Unspecified
Interventions: Drug: Escitalopram oxalate;   Device: transcranial direct current stimulation
Outcome Measures: Change in Hamilton Rating Scale for Depression, 17 items (HAMD17);   Change in Montgomery-Asberg Depression Rating Scale (MADRS);   Change in Beck Depression Inventory (BDI);   Hamilton Rating Scale for Depression, 17 items (HAMD17)
6 Not yet recruiting Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Agomelatine;   Drug: Escitalopram
Outcome Measures: Change from baseline in markers of sympathetic nervous system activity.;   Change from baseline in the magnitude of morning surge in blood pressure.;   To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.;   Change from baseline in insulin resistance.;   Change from baseline on markers of cardiac risk.
7 Unknown  Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
Conditions: Low Back Pain;   Depression
Interventions: Drug: Escitalopram;   Drug: Placebo
Outcome Measures: In comparison to placebo-treated patients, patients with treated with Cipralex report a significant reduction in depressive symptoms (>= 50% HAMD score) after 4 weeks of treatment.;   In comparison to placebo, subjects treated with Cipralex report a significant reduction in pain intensity (>= 50% reduction of pain questionnaire score or VAS) after 12 weeks of treatment.;   In comparison with placebo, subjects treated with Cipralex report a significant improvement in physical and everyday functioning after 12 weeks of treatment.;   Personality traits do not have a significant influence on outcome regarding depressive traits, pain intensity and functioning.;   Personality disorders are significantly influencing worse outcome regarding depressive traits, pain intensity and functioning.
8 Recruiting Brain Aging and Treatment Response in Geriatric Depression
Conditions: Mild Neurocognitive Disorder;   MCI;   Depression
Interventions: Drug: Escitalopram;   Drug: Memantine;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale (HDRS) scores;   Change in cognitive domain scores
9 Recruiting DECIFER: DEpression and Citalopram In First Episode Recovery
Conditions: Schizophrenia;   Schizophreniform Disorder
Interventions: Drug: Citalopram;   Behavioral: Psychoeducation;   Behavioral: Cognitive Behavioral Therapy (CBT);   Radiation: Functional Magnetic Resonance Imaging (fMRI);   Drug: Placebo
Outcome Measures: Calgary Depression Scale for Schizophrenia (CDSS);   Scale for the Assessment of Negative Symptoms (SANS);   Brief Psychiatric Rating Scale (BPRS);   InterSePT Scale for Suicidal Thinking (ISST);   Heinrich Quality of Life Scale (QOL)
10 Unknown  The Effects of Escitalopram on Cytokines
Condition: Depression
Intervention: Drug: Escitalopram
Outcome Measures: The changes in cytokines;   The changes in Hamilton Depression Rating Scale
11 Unknown  Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)
Condition: Major Depression
Interventions: Drug: escitalopram;   Drug: nortriptyline
Outcome Measures: Hamilton depression rating scale;   Drop out due to side-effects of drugs
12 Not yet recruiting The ISLAND Study: InSuLa Assessed Needs for Depression
Condition: Depression
Interventions: Drug: Escitalopram;   Behavioral: Cognitive Behavioral Therapy;   Other: Combination treatment (Escitalopram + CBT)
Outcome Measures: Remission from major depressive episode;   Response to treatment
13 Unknown  Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Conditions: Depression;   Continuous Antidepressant Abuse;   Adverse Reaction to Drug
Intervention: Drug: Escitalopram
Outcome Measures: antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks;   biological value at 0 week and 8 weeks
14 Recruiting Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Condition: Alcohol Dependence
Intervention: Drug: citalopram
Outcome Measures: Craving for alcohol in type B alcohol dependence with citalopram compared to placebo;   Striatal dopamine receptor availability in type B alcohol dependence with citalopram, compared to placebo
15 Unknown  Neuroprotective/Neurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder
Condition: Posttraumatic Stress Disorder
Intervention: Drug: escitalopram (Lexapro)
Outcome Measures: Changes from baseline in brain structure, function, and biochemical metabolism, analyzed using the computational approach;   Change from baseline in Clinician-administered PTSD scale scores at 1st week;   Change from baseline in Clinician-administered PTSD scale scores at 4th weeks;   Change from baseline in Clinician-administered PTSD scale scores at 8th weeks;   Change from baseline in Hamilton depression rating scale scores at 1st week;   Change from baseline in Hamilton anxiety rating scale scores at 1st week;   Number of participants with adverse events;   Change from baseline in Hamilton depression rating scale scores at 4th weeks;   Change from baseline in Hamilton depression rating scale scores at 8th weeks;   Change from baseline in Hamilton anxiety rating scale scores at 4th weeks;   Change from baseline in Hamilton anxiety rating scale scores at 8th weeks
16 Unknown  Citalopram for Cocaine Dependence
Condition: Cocaine Dependence
Interventions: Drug: Citalopram;   Drug: Placebo
Outcome Measures: Abstinence;   Cocaine Use Days;   Cocaine-negative Urines;   Retention in Treatment
17 Recruiting A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
Condition: Depressive Disorder, Major
Intervention: Drug: Escitalopram
Outcome Measures: Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF);   Change From Baseline in Sheehan Disability Scale (SDS);   Remission Rate at Week 8;   Onset of Effect Rate at Week 1;   Onset of Effect Rate at Week 2;   Change From Baseline to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Scores;   Change From Baseline to Week 8 in Hamilton Anxiety Scale (HAMA) Scores;   Change From Baseline to Week 8 in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Scores
18 Unknown  Cipralex® for Anxiety Disorders in Adolescents
Condition: Anxiety Disorder
Intervention: Drug: Cipralex®
Outcome Measures: Treatment Efficacy;   Physiological response to stress;   Suicide risk
19 Unknown  Intervention Study of Depression in Breast Cancer Patients
Conditions: Breast Cancer;   Depression;   Anxiety
Interventions: Behavioral: CBT and clinical management;   Drug: Escitalopram;   Behavioral: Clinical Management;   Drug: Sugar pill
Outcome Measures: Change from Baseline in Depression and Anxiety at 24 weeks, Hamilton Depression Rating Scale (HAMD-17), Hamilton Anxiety Scale (HAMA);   Hospital Anxiety and Depression Scale (HAD), Quality of Life (FACT-B), well-being index, pain score, Athens Insomnia Scale
20 Recruiting Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults
Condition: Healthy Young and Elderly Volunteers
Interventions: Drug: Intravenous Citalopram;   Drug: Normal Saline
Outcome Measures: BOLD fMRI Response;   Genetics and Cognitive/Emotional Change